Research Papers:

Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

Xia-Ying Kuang _, Li Chen, Zhi-Jie Zhang, Yi-Rong Liu, Yi-Zi Zheng, Hong Ling, Feng Qiao, Shan Li, Xin Hu and Zhi-Ming Shao

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:22227-22238. https://doi.org/10.18632/oncotarget.4276

Metrics: PDF 2449 views  |   HTML 2861 views  |   ?  


Xia-Ying Kuang1,2,*, Li Chen1,2,*, Zhi-Jie Zhang4, Yi-Rong Liu1,2, Yi-Zi Zheng1,2, Hong Ling2, Feng Qiao2, Shan Li2, Xin Hu2, Zhi-Ming Shao1,2,3

1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

3Institutes of Biomedical Science, Fudan University, Shanghai, China

4Department of Epidemiology and Biostatistics, School of Public Health, Fudan University, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Zhi-Ming Shao, e-mail: [email protected]

Xin Hu, e-mail: [email protected]

Keywords: stathmin, phosphorylation, breast cancer, prognostic model, paclitaxel

Received: March 11, 2015     Accepted: June 01, 2015     Published: June 13, 2015


Currently, Stathmin1 (STMN1) and phospho-STMN1 levels in breast cancers and their clinical implications are unknown. We examined the expression of STMN1 and its serine phospho-site (Ser16, Ser25, Ser38, and Ser63) status by immunohistochemistry. Using Cox regression analysis, a STMN1 expression signature and phosphorylation profile plus clinicopathological characteristics (STMN1-E/P/C) was developed in the training set (n = 204) and applied to the validation set (n = 106). This tool enabled us to separate breast cancer patients into high- and low-risk groups with significantly different disease-free survival (DFS) rates (P < 0.001). Importantly, this STMN1-E/P/C model had a greater prognostic value than the traditional TNM classifier, especially in luminal subtype breast cancer (P = 0.002). Further analysis showed that patients in the low-risk group would benefit more from adjuvant paclitaxel-based chemotherapy (P = 0.002). In conclusion, the STMN1-E/P/C signature is a reliable prognostic indicator for luminal subtype breast cancer and may predict the therapeutic response to paclitaxel-based treatments, potentially facilitating individualized management.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4276